Stage IV CRC patients with wild-type KRAS status demonstrate improved progression-free survival (PFS), objective response and overall survival (OS) after receiving chemotherapy in combination with anti-EGFR MoAb therapy, while those with KRAS mutations do not benefit from cetuximab or panitumumab [8, 9, 10, 11, 12, 13, 14]. This evidence concerns the gene KRAS and colorectal carcinoma.